Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPA-15406 (difamilast) ointment in infants with atopic dermatitis
jRCT2031220124Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of difamilast in atopic dermatitis (AD) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Success rate in Investigator's Global Assessment (IGA). Started Jun 2022; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031220124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220124.